RxDoctor Payments Data

Robert Collins, MD

Internal Medicine · Columbia, SCNPI 1225477425

Payments from drug & device makers

$10,534in general payments, 2019–2025

Across 486 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$651
  • Bristol Myers Squibb$522
  • Pfizer$518
  • AstraZeneca$518
  • Merck$518
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$10,522100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis43$1,035
Johnson & Johnson(2 entities)31$651
Bristol Myers Squibb28$522
Pfizer31$518
AstraZeneca(2 entities)30$518
Merck19$518
Takeda Pharmaceuticals U.S.A., Inc.19$394
Lilly USA, LLC16$362
AbbVie15$306
Astellas Pharma US Inc16$302
Incyte Corporation14$281
Daiichi Sankyo Inc.11$266
E.r. Squibb & Sons, L.L.C.16$254
Heron Therapeutics, Inc.1$254
Gilead12$231
Genentech USA, Inc.13$227
EMD Serono, Inc.9$209
Seagen Inc.13$208
Amgen5$205
Eagle Pharmaceuticals, Inc.4$187
Jazz Pharmaceuticals Inc.10$181
Bayer10$172
Deciphera Pharmaceuticals Inc.6$154
Octapharma USA, Inc.1$152
Array Biopharma Inc10$142
Sanofi5$140
Regeneron Healthcare Solutions, Inc.6$135
Novocure Inc.2$124
Exelixis Inc.8$121
Puma Biotechnology, Inc.6$121
Janssen Scientific Affairs, LLC1$119
Foundation Medicine, Inc.1$115
Rigel Pharmaceuticals, Inc.4$100
Ipsen Biopharmaceuticals, Inc4$86
Eisai Inc.4$80
Sumitomo Pharma America, Inc.4$80
GSK4$77
Boehringer Ingelheim3$70
Kyowa Kirin, Inc.4$68
Karyopharm Therapeutics Inc.4$65
ADC Therapeutics America, Inc.3$58
Mirati Therapeutics, Inc.3$56
Pharmaessentia USA Corporation2$53
AVEO Pharmaceuticals, Inc.3$51
Servier Pharmaceuticals LLC2$48
Sobi, Inc3$45
Beigene USA, Inc.2$35
Blueprint Medicines Corporation2$35
Beone Medicines USA, Inc.2$33
Morphosys, US Inc.2$29
Acrotech Biopharma Inc.1$29
Secura Bio, Inc.1$27
Immunocore Limited1$26
Pharmacyclics LLC, An Abbvie Company2$26
Tersera Therapeutics LLC1$24
Taiho Oncology, Inc.1$21
CTI Biopharma Corp.1$20
Genmab U.S., Inc.1$19
Macrogenics, Inc.1$19
Spectrum Pharmaceuticals Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,534 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$6,774,567
Medicare patients
1,522
Services billed
316,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib62$974,414
RevlimidLenalidomide44$767,671
PomalystPomalidomide12$269,875
IbrancePalbociclib18$266,853
LynparzaOlaparib21$204,515
KisqaliRibociclib Succinate14$198,676
Everolimus15$132,912
VenclextaVenetoclax16$66,033
Abiraterone Acetate15$47,588
EliquisApixaban40$30,063
XareltoRivaroxaban19$20,019
Anastrozole259$8,563
Letrozole97$3,528
Exemestane17$2,491
Acyclovir95$1,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$26$974,41462 claims
Bristol Myers SquibbRevlimid$522$767,67144 claims
PfizerIbrance, Eliquis$518$296,91558 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$254$269,87512 claims
AstraZenecaLynparza$518$204,51521 claims
NovartisKisqali$1,035$198,67614 claims
AbbVieVenclexta$306$66,03316 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$119$47,58815 claims
Johnson & JohnsonXarelto$651$20,01919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →